Knowing that epigenetic regulation of the Birc5 promoter is essential to YM155 activity, it would be interesting to test the combination of histone acetyltransferase (p300/CBP) inhibitors or demethylase (JMJD3) inhibitors with YM155 in the treatment of cancers listed in Table 1. This evidence concerns the gene EP300 and cancer.